@voniesk5's testosterone pellet therapy claims, fact-checked

What did @voniesk5 actually say?

One week after receiving a subcutaneous testosterone and estrogen pellet, @voniesk5 reported two main improvements: dramatically better sleep and less daytime fatigue. She said she used to wake at 2 or 3 a.m. and stay up until morning, but is now sleeping until 5 a.m. She also noted she no longer feels like she needs a noon nap. On the downside, she flagged fluid retention and breast tenderness, calling both temporary, and mentioned picking up evening primrose oil to manage the tenderness.

Worth noting: she kept this honest and specific. She did not claim a cure, did not overstate the timeline, and acknowledged side effects openly. That is not nothing on a platform where hormone therapy content often reads like a multilevel marketing pitch.

Does the science back this up?

Partly, but the timing is where things get complicated. Pellets release hormones gradually, and most pharmacokinetic data suggests testosterone from subcutaneous pellets does not reach stable serum levels until three to four weeks post-insertion. A week in, she may be experiencing real early effects, or she may be experiencing a significant placebo response. Both are plausible.

On sleep: testosterone does appear to influence sleep architecture in women. A 2019 study by Davis et al. in the journal Menopause found that testosterone therapy in perimenopausal and postmenopausal women was associated with improvements in sleep quality, though most benefit was observed over weeks to months, not days. The fatigue improvement is similarly plausible but hard to pin on pellet absorption this early. Fluid retention and breast tenderness in week one are consistent with the estrogen component of the pellet, not testosterone, and are well-documented early side effects of estrogen initiation.

What did they get wrong (or right)?

She got the side effects right. Breast tenderness, which she calls "booby timbriness," is a common early complaint with estrogen therapy, and fluid retention is consistent with initial estrogen exposure. These are not dangerous, and her instinct to wait them out is reasonable.

On evening primrose oil: the evidence is weak. A 2010 Cochrane review by Maclennan et al. found no reliable data supporting evening primrose oil for breast pain or hormone-related symptoms. She should know she is reaching for an intervention with thin scientific support.

What she got wrong by omission is more concerning. Pellet therapy is not FDA-approved. It is compounded, meaning the dose consistency between batches and providers varies in ways that injectable or transdermal forms do not. She presents the procedure as straightforwardly routine without acknowledging that pellets exist in a regulatory gray zone. Viewers following her journey should understand that context before booking an appointment.

What should you actually know?

Subcutaneous hormone pellets are compounded products. That means they are not held to the same manufacturing standards as FDA-approved testosterone formulations. Pellet dosing is also not easily reversible. If a pellet is over-dosed, you cannot remove it the way you can stop a patch or reduce a gel application. A 2020 review by Pinkerton and Shapiro in Menopause noted that while pellets are used clinically, there is insufficient long-term safety and efficacy data compared to approved delivery methods.

That does not mean pellets are dangerous or wrong for everyone. It means the decision deserves more scrutiny than a week-one TikTok can provide. Women experiencing the symptoms @voniesk5 describes, including disrupted sleep, fatigue, and hormonal imbalance, should talk to a licensed clinician who can review serum levels before and after therapy, not just respond to how someone feels seven days post-insertion.

• Testosterone pellets are not FDA-approved. They are compounded products with variable dosing.
• Serum levels from pellets typically stabilize at three to four weeks, not one week.
• Evening primrose oil has limited evidence for hormone-related breast tenderness.
• Fluid retention and breast tenderness in week one are most likely estrogen-driven, not testosterone-driven.
• Sleep improvements from testosterone in women are documented, but usually over longer timeframes than seven days.